창상관리용 바이오로직스 시장 보고서 : 제품 유형별, 창상 유형별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global wound care biologics market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.4 Billion by 2034, exhibiting a growth rate (CAGR) of 6.77 % during 2026-2034. The market is experiencing steady growth driven by the rising incidence of chronic wounds, advancements in biotechnology, and a shift towards minimally invasive patient-centric solutions, which is driving demand for innovative biologic therapies in wound management.

WOUND CARE BIOLOGICS MARKET ANALYSIS:

• Market Growth and Size: The global market is experiencing robust growth, driven by an increasing prevalence of chronic wounds, burns, and surgical procedures, contributing to a significant expansion in market size.
• Major Market Drivers : Key drivers include the rising incidence of chronic diseases, aging populations, and the demand for advanced wound care solutions, with biologic therapies addressing the complexities of wound healing.
• Technological Advancements: Rapid technological advancements in biotechnology, regenerative medicine, and the integration of advanced materials contribute to the development of more effective and personalized wound care biologics.
• Industry Applications: These biologics find application across various wound types, including ulcers, surgical wounds, burns, and traumatic wounds, reflecting their versatility and effectiveness in managing diverse clinical scenarios.
• Geographical Trends: Asia Pacific emerges as the largest market segment, driven by rapid industrialization, increasing healthcare investments, and a growing population, while North America and Europe maintain significant market presence.
• Competitive Landscape: Key players are actively investing in research and development, forming strategic collaborations, and expanding their global footprint through acquisitions, positioning themselves as leaders in the competitive market.
• Challenges and Opportunities: Challenges include resistance to change, data security concerns, and the need for widespread adoption, while opportunities lie in sustainability-focused solutions, meeting evolving consumer demands, and navigating global supply chain complexities.
• Future Outlook: The future outlook for the market appears promising, with sustained growth anticipated as industries continue to prioritize advanced wound care solutions. Continued technological advancements, expanding applications, and a focus on sustainability position the market for continued evolution and innovation in the coming years.

WOUND CARE BIOLOGICS MARKET TRENDS:

Increasing incidence of chronic wounds and ulcers

The growing prevalence of chronic wounds and ulcers, fueled by factors such as aging populations, diabetes, and vascular diseases, is a major driver for the market. As the global healthcare burden associated with chronic wounds rises, there is a heightened demand for advanced therapeutic solutions. Wound care biologics, including growth factors, extracellular matrices, and stem cell-based therapies, offer promising avenues for accelerating the healing process and addressing the complexities of chronic wounds that often resist conventional treatments. These innovative biologics play a crucial role in promoting tissue regeneration and reducing inflammation, essential aspects in chronic wound management. Growth factors, like platelet-derived growth factor and epidermal growth factor, stimulate cell proliferation and tissue repair. Extracellular matrices provide a scaffold for cell migration and tissue rebuilding, enhancing wound closure. Stem cell therapies contribute by promoting tissue regeneration and modulating the immune response. The personalized nature of these biologics allows for tailored treatments, optimizing outcomes for patients with diverse wound characteristics. Continued research and development in wound care biologics hold the promise of further breakthroughs, revolutionizing the landscape of chronic wound management in the evolving field of healthcare.

Rapid advancements in biotechnology and regenerative medicine

Significant strides in biotechnology and regenerative medicine are propelling the market forward. Innovations in tissue engineering, biomaterials, and the understanding of cellular mechanisms have led to the development of biological therapies with enhanced healing capabilities. The integration of cutting-edge technologies, such as gene therapy and tissue regeneration, into wound care biologics underscores the industry's commitment to providing more effective and personalized treatment options for complex wounds. Moreover, the convergence of artificial intelligence and biotechnology has facilitated the identification of novel therapeutic targets, fostering the creation of biologics tailored to individual patient profiles. Gene therapy, with its ability to modify cellular functions at a genetic level, holds promise in addressing underlying causes of chronic wounds. Tissue regeneration techniques, guided by advanced imaging and diagnostic tools, enable precise interventions. As these scientific frontiers expand, the synergy between technology and biologics is reshaping the wound care landscape. This amalgamation not only augments the efficacy of existing treatments but also opens avenues for groundbreaking solutions that may redefine the future of wound care.

Rising focus on minimally invasive and patient-centric approaches

A paradigm shift towards minimally invasive and patient-centric wound care approaches is driving the adoption of biologics. Patients and healthcare providers increasingly seek interventions that promote faster healing, reduce pain, and improve overall quality of life. Wound care biologics, with their capacity to stimulate natural healing processes, align with this trend. As the industry continues to prioritize therapies that enhance patient comfort and outcomes, the demand for biologic solutions in wound care is expected to grow, fostering a more holistic and personalized approach to wound management. This shift towards patient-centric care is not only reflected in the efficacy of biologics but also in their convenience and reduced invasiveness compared to traditional treatments. Biologics offer targeted interventions that minimize trauma, supporting quicker recovery and decreased discomfort for patients. The emphasis on enhancing quality of life extends to the development of user-friendly application methods and home-based care options. As healthcare evolves to prioritize individual needs, the trajectory of wound care biologics aligns seamlessly with this patient-centric paradigm, marking a transformative era where advanced therapies not only heal wounds but also prioritize the overall well-being and satisfaction of those undergoing treatment.

WOUND CARE BIOLOGICS INDUSTRY SEGMENTATION:

Breakup by Product:

• Biologic Skin Substitutes
  • Human Donor Tissue-Derived Products
  • Acellular Animal-Derived Products
  • Biosynthetic Products
• Topical Agents

Biologic skin substitutes account for the majority of the market share

The market segmentation based on products includes a significant category devoted to biologic skin substitutes. These substitutes, derived from biological sources, offer advanced wound healing capabilities by providing a scaffold for tissue regeneration. They contribute to accelerated wound closure, reduced scarring, and improved healing outcomes, making them a crucial component in the treatment of complex wounds and burns. As the demand for regenerative and personalized wound care solutions rises, biologic skin substitutes represent a cornerstone in the market.

Within the product segmentation, the topical agents play a vital role in the market. Topical agents encompass a diverse range of biological formulations such as growth factors, cytokines, and enzymes, designed for application directly to the wound site. These agents facilitate wound healing by promoting cell proliferation, tissue repair, and modulating the inflammatory response. Topical agents offer versatility and ease of application, making them suitable for a wide array of wounds, including chronic ulcers and acute injuries. With a focus on enhancing wound closure and minimizing infection risks, they continue to be a pivotal component in the evolving landscape of wound care biologics.

Breakup by Wound Type:

• Ulcers
  • Diabetic Foot Ulcers
  • Venous Ulcers
  • Pressure Ulcers
  • Others
• Surgical and Traumatic Wounds
• Burns

Ulcers hold the largest share in the industry

The market segmentation based on wound type in the market places a spotlight on the ulcers segment, which stands out as the largest category. Chronic wounds, including diabetic ulcers and venous ulcers, present a significant healthcare challenge globally. Biologic therapies, such as growth factors and skin substitutes, play a pivotal role in addressing the complexities of ulcer healing by promoting tissue regeneration and mitigating the factors hindering normal wound closure. The ulcer segment is witnessing sustained growth due to the increasing prevalence of chronic wounds, emphasizing the critical need for advanced biologic interventions to enhance healing outcomes and mitigate the economic and healthcare burden associated with ulcer management.

Within the market's segmentation by wound type, the surgical and traumatic wounds segment holds a crucial position. Surgical procedures and traumatic injuries often necessitate interventions that expedite the healing process and minimize complications. Biologic therapies designed for these wounds include growth factors and tissue matrices that aid in tissue repair and regeneration. The demand for biologics in this segment is driven by the imperative to improve postoperative recovery, reduce scarring, and enhance the overall efficacy of wound healing in cases of trauma, surgeries, and other acute injuries.

The burns segment is a significant category in the wound care biologics market, catering to the unique challenges associated with burn injuries. Biologic interventions, such as skin substitutes and growth factors, play a crucial role in promoting tissue regeneration, minimizing scarring, and preventing complications in burn wound healing. With a focus on providing optimal wound care solutions for burn patients, the Burns segment underscores the importance of biologics in addressing the specialized needs of this patient population. The market's emphasis on advanced biologic therapies for burns reflects a commitment to improving outcomes and enhancing the quality of life for individuals affected by burn injuries.

Breakup by Application:

• Acute Wound
• Chronic Wound
• Surgical Wound

Chronic wound represents the leading market segment

The chronic wound segment is a significant category in the wound care biologics market, encompassing wounds that persist over an extended period, such as diabetic ulcers and venous ulcers. Biologic interventions for chronic wounds aim to address the underlying factors hindering normal healing, providing advanced solutions to stimulate tissue repair and regeneration. Growth factors, skin substitutes, and other biologic therapies play a crucial role in managing chronic wounds, contributing to improved outcomes and quality of life for patients grappling with persistent injuries.

In the market, the segmentation based on application includes the acute wound segment, representing wounds typically resulting from sudden injuries or surgical procedures. Biologic interventions in this segment focus on expediting the healing process, minimizing complications, and promoting optimal tissue regeneration. Biologic therapies, such as growth factors and tissue matrices, play a pivotal role in enhancing the body's natural healing mechanisms for acute wounds, addressing the specific needs of patients undergoing surgical procedures or experiencing sudden injuries.

The surgical wound segment within the wound care biologics market pertains to wounds resulting from planned surgical procedures. Biologic interventions in this segment focus on optimizing postoperative recovery, minimizing scarring, and promoting efficient wound closure. Growth factors, tissue matrices, and other biologic therapies are employed to enhance tissue repair and regeneration, supporting the overall success of surgical interventions. As the demand for advanced wound care solutions in surgical settings rises, the Surgical Wound segment remains a key focus area for the application of biologic therapies.

Breakup by End-User:

• Hospitals
• ASCs
• Burn Centres and Wound Clinics

Hospitals represents the leading market segment

The market segmentation based on end-users in the wound care biologics market includes the hospitals segment, representing a major stakeholder. Hospitals serve as primary hubs for wound management, encompassing a diverse range of acute and chronic wounds. Biologic interventions, such as growth factors and skin substitutes, are extensively employed in hospital settings to address various wound types arising from surgeries, injuries, or chronic conditions. The hospital segment is crucial in driving the adoption of biologic therapies, reflecting the broader trend of advancing wound care within comprehensive healthcare facilities.

The ASCs segment plays a significant role in the wound care biologics market, particularly as the trend towards outpatient procedures and ambulatory care gains momentum. Ambulatory Surgical Centers focus on providing specialized care more conveniently and cost-effectively. Biologic interventions in ASCs cater to surgical wounds, emphasizing the importance of efficient wound healing in the ambulatory setting. As ASCs continue to grow in prominence, the adoption of biologic therapies reflects the evolving landscape of wound care in outpatient environments.

The burn centres segment is a specialized category within the wound care biologics market, addressing the unique requirements of patients with burn injuries. Biologic therapies, such as skin substitutes and growth factors, play a critical role in burn wound care by promoting tissue regeneration and minimizing scarring. Burn centres, specialized in managing complex burn cases, rely on biologic interventions to optimize outcomes, reflecting the crucial role of biologics in addressing the distinctive challenges associated with burn injuries.

The wound clinics segment represents specialized centers solely dedicated to wound care and management. Biologic therapies find extensive application in wound clinics, catering to a wide array of acute and chronic wounds. These clinics, often equipped with advanced technologies and specialized healthcare professionals, leverage biologic interventions to provide tailored and comprehensive wound care solutions. This segment showcases the increasing recognition of biologic therapies as integral components in the multidisciplinary approach to wound management, emphasizing the importance of specialized care in achieving optimal healing outcomes.

Breakup by Region:

• Asia Pacific
• Europe
• North America
• Middle East and Africa
• Latin America

North America leads the market, accounting for the largest wound care biologics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Asia Pacific, Europe, North America, Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

North America stands as a key player in the wound care biologics market, driven by technological advancements, high healthcare expenditures, and a significant burden of chronic diseases. The United States and Canada lead in the adoption of biologic therapies for wound care across diverse healthcare settings. The region's emphasis on research and development, coupled with a proactive regulatory environment, fosters innovation in the field of wound care biologics. North America's substantial market share reflects a proactive approach to addressing the complexities of wound healing and a commitment to advancing patient-centric solutions.

Asia Pacific emerges as a key player in the market, driven by the region's rapid industrialization, increasing healthcare investments, and growing population. Countries like China, Japan, and India are witnessing a surge in chronic diseases, contributing to a higher prevalence of wounds. The demand for advanced wound care solutions, including biologic therapies, is escalating in response to the evolving healthcare landscape and the focus on improving patient outcomes. Asia Pacific's dominance in the market reflects a burgeoning need for innovative wound care interventions amid the region's dynamic economic and demographic shifts.

Europe holds a prominent position in the wound care biologics market, characterized by well-established healthcare infrastructure and a proactive approach towards adopting advanced medical technologies. Countries such as Germany, the United Kingdom, and France are at the forefront of integrating biologic therapies into wound care practices. The region's aging population and the prevalence of chronic diseases contribute to a substantial demand for effective wound management solutions. Europe's robust market presence underscores a commitment to providing high-quality healthcare services and leveraging innovative biologic interventions for improved patient outcomes.

The Middle East and Africa exhibit a growing presence in the market, driven by increasing healthcare awareness, infrastructure development, and a rising burden of chronic diseases. Countries in the Middle East, including the United Arab Emirates and Saudi Arabia, are investing in advanced medical technologies, contributing to the adoption of biologic therapies in wound care. The region's unique healthcare challenges, such as a high prevalence of diabetes, position wound care biologics as essential in addressing the diverse wound management needs across these nations.

Latin America is a notable segment in the market, characterized by a growing emphasis on healthcare modernization and a rising prevalence of chronic conditions. Countries like Brazil and Mexico contribute significantly to the adoption of biologic interventions in wound care. The region's evolving healthcare infrastructure and increasing awareness about advanced wound care solutions drive the demand for biologic therapies. Latin America's market presence underscores the region's commitment to enhancing healthcare outcomes and addressing the complexities associated with wound management through innovative biologic interventions.

LEADING KEY PLAYERS IN THE WOUND CARE BIOLOGICS INDUSTRY:

The key players in the market are actively engaged in strategic initiatives to maintain their competitive edge and meet the evolving demands of the healthcare landscape. These industry leaders focus on continuous research and development, investing in cutting-edge technologies to enhance the efficacy of biologic therapies for wound care. Collaboration and partnerships with healthcare institutions, research organizations, and other stakeholders are common strategies to broaden the scope of their products and services. Additionally, market leaders are expanding their global presence through acquisitions and mergers, aiming to strengthen their market position and diversify their portfolio. Moreover, there is a noticeable emphasis on sustainable practices, with key players integrating eco-friendly approaches in the development and production of biologic therapies.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Anika Therapeutics, Inc.
• Convatec Inc.
• Integra LifeSciences Corporation
• Kerecis
• MIMEDX Group, Inc.
• Molnlycke AB
• Organogenesis Inc.
• Skye Biologics Holdings, LLC
• Smith & Nephew
• Stryker Corporation

LATEST NEWS:

• November 22, 2023: Smith+Nephew, the worldwide medical technology enterprise, has officially declared its commitment to acquiring CartiHeal, the innovator behind Agili-C, an advanced sports medicine technology designed for knee cartilage regeneration. According to the agreement, Smith+Nephew is set to provide an initial cash payment of $180 million upon completion, with an additional potential payment of up to $150 million dependent on financial performance.
• April 28, 2023: Molnlycke has secured a fresh multicurrency revolving credit facility amounting to EUR 350 million. This facility spans a duration of five years, accompanied by two one-year extension options, and is designated as a contingency fund for general corporate needs. It serves as a refinancing measure for the prior undrawn revolving credit facility established in 2017.
• July 6, 2023: Integra LifeSciences Holdings Corporation (NASDAQ: IART), a prominent global medical technology firm, has reported favorable clinical and economic outcomes stemming from the utilization of the Codman(R) Bactiseal(R) External Ventricular Drain (EVD) catheter set in addressing hydrocephalus complications arising from aneurysmal subarachnoid hemorrhage (aSAH) in patients. The real-world study, supported by an independent grant from Integra, was carried out at the University Hospital Gemelli in Rome, Italy.

WOUND CARE BIOLOGICS MARKET REPORT SCOPE:

Key Questions Answered in This Report:

• How has the global wound care biologics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global wound care biologics market?
• What is the impact of each driver, restraint, and opportunity on the global wound care biologics market?
• What are the key regional markets?
• Which countries represent the most attractive wound care biologics market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the wound care biologics market?
• What is the breakup of the market based on the wound type?
• Which is the most attractive wound type in the wound care biologics market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the wound care biologics market?
• What is the breakup of the market based on the end-user?
• Which is the most attractive end-user in the wound care biologics market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global wound care biologics market?

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the wound care biologics market from 2020-2034.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global wound care biologics market.
• The study maps the leading, as well as the fastest-growing, regional markets.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the wound care biologics industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
• NEED MORE HELP?
• Speak to our experienced analysts for insights on the current market
• scenarios.
• Include additional segments and countries to customize the report as per
• your requirement.
• Gain an unparalleled competitive advantage in your domain by understanding
• how to utilize the report and positively impacting your operations and
• revenue.
• For further assistance, please connect with our analysts.
• Personalize this research
• Triangulate with your data
• Get data as per your format and definition
• Gain a deeper dive into a specific application, geography, customer, or
• competitor
• Any level of personalization
• GET IN TOUCH WITH US
• Phone: +1-201-971-6302
• Phone: +91-120-433-0800
• Phone: +44-753-714-6104
• CLIENT TESTIMONIALS
• IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
• The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
• We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
• Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
• We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
• The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
• The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
• My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
• I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
• We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
• IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
• IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.
• I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand.
• I would also like to take this opportunity to inform you that we are greatly interested
• Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.
• The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.
• I'd like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer's success. The entire team and company are incredibly thankful for your dedication. Once again, thank you
• The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.
• One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We've worked with them a couple of times and we will keep working with them in future projects.
• We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.
• The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.
• The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.
• The report is excellent and has good amount of data and our team is extremely happy with the information provided.
• Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.
• Call
• Email
• We use cookies, including third-party, for better services. See our Privacy Policy for more. I ACCEPT X
• About Us
• IMARC Group is a leading market research company dedicated to providing data-driven insights and expert consulting services to support businesses in achieving their strategic objectives across diverse industries.
• Follow Us
• Quick Links
• Australia Market Research
• India Market Research
• Japan Market Research
• Europe Market Research
• US Market Research
• Blogs
• Press
• Releases
• Case
• Studies
• Information
• Career
• Terms & Conditions
• Privacy Policy
• Media Room
• Our
• Customers
• Become
• a Publisher
• FAQs
• News
• Sitemap
• Industries
• Aerospace and Defense
• Agriculture
• Automotive
• BFSI
• Chemicals and Materials
• Construction and Manufacturing
• Electronics and Semiconductor
• Energy and Mining
• Food and Beverages
• Healthcare
• Packaging
• Retail
• Technology an

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Wound Care Biologics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Product
• 5.5 Market Breakup by Wound Type
• 5.6 Market Breakup by Application
• 5.7 Market Breakup by End-User
• 5.8 Market Breakup by Region
• 5.9 Market Forecast

6 Market Breakup by Product

• 6.1 Biologic Skin Substitutes
  • 6.1.1 Market Trends
  • 6.1.2 Market Breakup by Type
    • 6.1.2.1 Human Donor Tissue-Derived Products
    • 6.1.2.2 Acellular Animal-Derived Products
    • 6.1.2.3 Biosynthetic Products
  • 6.1.3 Market Forecast
• 6.2 Topical Agents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Wound Type

• 7.1 Ulcers
  • 7.1.1 Market Trends
  • 7.1.2 Market Breakup by Type
    • 7.1.2.1 Diabetic Foot Ulcers
    • 7.1.2.2 Venous Ulcers
    • 7.1.2.3 Pressure Ulcers
    • 7.1.2.4 Others
  • 7.1.3 Market Forecast
• 7.2 Surgical and Traumatic Wounds
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Burns
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Acute Wound
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Chronic Wound
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Surgical Wound
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End-User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 ASCs
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Burn Centres and Wound Clinics
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 Asia Pacific
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Europe
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 North America
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Middle East and Africa
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Latin America
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Anika Therapeutics, Inc.
  • 15.3.2 Convatec Inc.
  • 15.3.3 Integra LifeSciences Corporation
  • 15.3.4 Kerecis
  • 15.3.5 MIMEDX Group, Inc.
  • 15.3.6 Molnlycke AB
  • 15.3.7 Organogenesis Inc.
  • 15.3.8 Skye Biologics Holdings, LLC
  • 15.3.9 Smith & Nephew
  • 15.3.10 Stryker Corporation